Peptide education
Bacitracin
Bacitracin zinc
Bacitracin is a mixture of related cyclic polypeptide antibiotics, mainly bacitracin A. A first-aid skin ointment is labeled to help prevent infection in minor cuts, scrapes, and burns. Separate sterile ophthalmic preparations have different labeling.
Bacitracin products differ by site and formulation. Studies of wound care have reported different infection rates in different clinical settings.
Overview
Quick answer
Skin ointment is not an eye preparation. FDA lists the specified single-ingredient eye ointment as unavailable. U.S. injectable approvals were withdrawn after safety concerns, including kidney injury and anaphylaxis.
What is the skin ointment for?
The cited OTC bacitracin zinc product is labeled as first aid to help prevent infection in minor cuts, scrapes, and burns.
Can that ointment go in the eye?
No. Its label says not to use it in the eyes. Sterile bacitracin ophthalmic ointment is a different product.
Does it work against every bacterium?
No. The ophthalmic label describes activity against many Gram-positive bacteria, including staphylococci and streptococci; susceptibility and the specific infection matter.
What happened to injectable bacitracin?
FDA withdrew the listed U.S. injectable approvals after concerns about kidney toxicity and serious allergic reactions. This action concerned injection, not the cited skin ointment.
Is the single-ingredient eye ointment available?
The FDA shortage record lists the specified single-ingredient ointment as unavailable. Other ophthalmic products can contain additional antibiotics, and availability can change.
Evidence
Evidence snapshot
Infections after bacitracin versus petrolatum in evaluable patients; the difference was not statistically significant.
Infections after bacitracin versus petrolatum in a separate emergency department study of selected uncomplicated wounds.
The active ingredient concentration in the cited skin ointment.
The skin label advises stopping use and seeking medical advice if a reaction develops.
Claims
Common claims vs evidence
| Claim | Human evidence | Verdict |
|---|---|---|
| Bacitracin always prevents a wound infection better than petrolatum. | A repaired-wound trial found fewer infections with bacitracin, while a dermatologic-surgery trial found no statistically significant overall difference. | The results depend on the wound population and clinical setting. |
| Bacitracin skin ointment and ophthalmic ointment are interchangeable. | The first-aid label excludes eye use. The separate single-ingredient ophthalmic label describes a sterile preparation for superficial eye infections; its listed product is unavailable. | The products have different labeling and intended sites. |
| The injectable product has the same safety profile as skin ointment. | FDA identified kidney toxicity and anaphylactic reactions as serious risks of injection. The skin label separately warns about allergic reactions. | Risks cannot be transferred from one route to another. |
Bottom line
Main takeaway
The first-aid ointment is for minor skin wounds, not the eyes.
Stop use and seek medical advice if a rash or another allergic reaction develops.
Two randomized wound studies had different populations, event rates, and results.
Identity
What it is
Bacitracin is a mixture of related cyclic polypeptides, mainly bacitracin A. This mixture is distinct from a product that combines bacitracin with other antibiotics. The single-ingredient ophthalmic label describes activity against many Gram-positive organisms when susceptible.
Products may contain bacitracin alone or alongside other antibiotics. The added ingredients and intended site change the product's labeling.
Use context
Routes, doses, and cycle patterns
The following details describe the cited U.S. first-aid skin product.
Human studies and product labels
Bacitracin zinc first-aid ointment
- Purpose
- Help prevent infection in minor cuts, scrapes, and burns
- Context
- OTC product label
- Route
- External skin use
- Amount
- A small amount, with 500 bacitracin units per gram of ointment
- Frequency
- One to three times daily after cleaning the affected area
- Duration
- No longer than one week unless directed by a clinician
The label says not to use the product in the eyes or over large areas. It advises asking a clinician about deep or puncture wounds, animal bites, and serious burns.
What varies
- Site: a skin product is not a sterile eye product.
- Ingredients: combinations add other antibiotics and their own allergy considerations.
- Availability: FDA lists a specific single-ingredient ophthalmic ointment as unavailable; availability can change.
Research
Research evidence
Two randomized trials examined wound infection prevention in different settings. Their findings should be read alongside the wound type and rate of infection, not as a single universal estimate.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| Dermatologic surgery | Outpatients with surgical wounds | Randomized, double-blind trial | Bacitracin ointment versus white petrolatum | Overall infection occurred in 4 of 444 versus 9 of 440 evaluable patients. | Few infections occurred, and the trial concerned dermatologic surgery. | Moderate |
| Emergency department wound repair | Patients with selected uncomplicated repaired wounds | Randomized, double-blind comparison of four ointments | Bacitracin, combination antibiotics, silver sulfadiazine, or petrolatum | Infection occurred in 6 of 109 bacitracin and 19 of 108 petrolatum wounds. | Puncture wounds and several higher-risk populations were excluded. | Moderate |
Cautions
Safety and unknowns
- The skin label advises stopping use and seeking medical advice for rash or another allergic reaction.
- In the surgical-wound trial, four bacitracin recipients and no petrolatum recipients developed allergic contact dermatitis.
- FDA identified nephrotoxicity and anaphylactic reactions as serious risks of the historical injectable product.
Product quality
Product identity and quality
Skin ointment and sterile ophthalmic ointment have different labeling and are not interchangeable.
A separately labeled ophthalmic combination contains bacitracin zinc and polymyxin B; it is not the single-ingredient product.
Intended site
The cited first-aid product specifically excludes use in the eyes.
Mechanism
How it is proposed to work
Bacitracin interferes with the transport system bacteria use to build their cell walls.
It binds undecaprenyl pyrophosphate, a lipid carrier involved in cell-wall production.
FAQ
Common questions
Can a skin ointment be used in the eye?
No. The cited first-aid skin label says not to use it in the eyes; ophthalmic ointments are separate sterile products.
Is the single-ingredient eye ointment available?
The FDA shortage record lists the specified single-ingredient ophthalmic ointment as unavailable. Other ophthalmic products can contain additional antibiotics, and availability can change.
Was bacitracin injection withdrawn?
Yes. FDA withdrew the listed injectable approvals after safety concerns including kidney toxicity and anaphylaxis.
Details
Technical details
Sources
References
- 1.
- 2.
- 3.
- 4.
FDA. Bacitracin ophthalmic ointment shortage record
The record describes the listed single-ingredient product; availability can change.
- 5.
- 6.
- 7.
PubMed. Randomized comparison of petrolatum and bacitracin after dermatologic surgery
PMID:8805732
- 8.
PubMed. Randomized comparison of topical antibiotics after uncomplicated wound repair
doi:10.1111/j.1553-2712.1995.tb03070.x PMID:7606610
- 9.
PubMed. Bacitracin target recognition and cell-wall synthesis
doi:10.1073/pnas.1308268110 PMID:23940351